SciELO - Scientific Electronic Library Online

 
vol.30 issue6Intermediate β thalassemia in a pregnant womanMicroangiopathic hemolytic anemia induced by tacrolimus and ciclosporine A author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista Brasileira de Hematologia e Hemoterapia

Print version ISSN 1516-8484On-line version ISSN 1806-0870

Abstract

SANTOS, Paulo S. S.; GAMBIRAZI, Liane M.; FELIX, Valtuir B.  and  MAGALHAES, Marina Helena C. G.. Jaw osteonecrosis in patients with neoplastic diseases taking bisphosphonates. Rev. Bras. Hematol. Hemoter. [online]. 2008, vol.30, n.6, pp.501-504. ISSN 1806-0870.  https://doi.org/10.1590/S1516-84842008000600016.

The use of bisphosphonates among patients affected by osteolytic diseases, such as multiple myeloma, metastatic bone lesions and osteoporosis has been associated with the risk of osteonecrosis of the jaws. Bisphosphonates are found in areas of the bone that are undergoing inflammation or resorption. They are phagocytosed and internalized by osteoclasts. Once in the bone, these bisphosphonates cause apoptosis or cell death of the osteoclasts and as a result they may inhibit osteoclast-mediated bone resorption. Bisphosphonates seem to affect osteoclasts when it comes to both numbers and function. Although bisphosphonates are potent and valuable inhibitors of osteoclastic bone lesions, several unanswered questions exist regarding the risk of developing osteonecrosis and the management of this complication. This study reports two clinical cases of osteonecrosis of the jaws associated with the use of bisphosphonates. According to the findings, the two patients (women) with different neoplasms: multiple myeloma and breast cancer with metastatic bone lesions presented some signs and symptoms of osteonecrosis.

Keywords : Osteonecrosis; bisphosphonates; maxillary diseases.

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License